About ticagrelor
P2Y12 platelet aggregation inhibitor
Used for
- Reduces heart attack, stroke, and cardiovascular death risk after acute coronary syndrome.
- Prevents clotting complications after certain heart attacks or coronary stent placement.
Usual adult dose
Usually 90 mg twice daily during the first year after acute coronary syndrome, with low-dose aspirin.
Common side effects
- Bleeding or bruising
- Shortness of breath
- Slow heartbeat
- Nausea or diarrhea
Important warnings
- Can cause serious or fatal bleeding; bleeding may take longer to stop.
- Do not stop without medical direction; stopping can increase heart attack or stent-clot risk.
- Avoid aspirin doses above 100 mg daily unless specifically directed.
- Tell clinicians before surgery; treatment may need to be paused.
Pregnancy
Use only when needed; human pregnancy information is limited, and bleeding risks require clinical assessment.
Breastfeeding
It is unclear whether ticagrelor passes into human milk; discuss treatment and feeding with a clinician.
Interactions
- Strong CYP3A inhibitors, such as clarithromycin, can raise ticagrelor levels.
- Strong CYP3A inducers, such as rifampin, can reduce effectiveness.
- Anticoagulants and other antiplatelet medicines increase bleeding risk.
- High-dose simvastatin or lovastatin may increase muscle-related side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.